Information in Package Inserts: A study in Eastern India

H. Mishra, Harihar Dikshit, L. Mohan, Manish Kumar, P. Manjhi
{"title":"Information in Package Inserts: A study in Eastern India","authors":"H. Mishra, Harihar Dikshit, L. Mohan, Manish Kumar, P. Manjhi","doi":"10.7439/IJPR.V6I12.3657","DOIUrl":null,"url":null,"abstract":"Introduction: Package insert (PI) is the printed leaflet available with the medicines containing information about the drug based on regulatory guidelines for its safe and effective use. Information in a PI is incorporated since the developmental phase of a pharmaceutical product with careful scrutiny of available information. PI contains evidenced based information about a drug, updated from time to time as soon as relevant preclinical and clinical data were obtained. Various studies had shown poor compliance 50-60% to the medicine prescribed for the treatment of chronic conditions like hypertension, diabetes and dyslipidemia. These diseases proved to be major cause of mortality and morbidity related to cardiovascular diseases in India. The information of the PI has an important impact on patients compliance and hence effectiveness of the drug used and for health professionals they can serve as reliable and accurate sources of drug information. Material & Methods: Present study was observational and Prospective with study duration of 1 month. 93 package inserts were collected from different pharmacies of the Patna on request. Analysis of content of Package Insert was based on criteria laid down by Indian Drug and Cosmetic Rules, 1945 under section 6.2 of schedule D. Result: A total number of 106 PI were received, among which 93 PIs were analysed for the result remaining 13 PIs were discarded due to duplicity and unauthenticity. Out of them, 87 were from Indian pharmaceutical companies and 6 from multinational companies [Graph-2]. All PIs of antihypertensives and hypolipedemic were of oral preparations. Out of 93 PIs 37 were antihypertensives, 34 were antidiabetics and 22 hypolipidemics. Out of 34 anti-diabetic PIs, 22 (59.6%) were oral and 12 (40.4%) were injectable preparations. Out of 93 PIs, 40 (43%) belonged to Grade A (including all injectable preparations) and remaining 53 (57%) to Grade B. No PIs belongs to Grade C.87 PIs were from Indian companies and 6 PIs were from multinational companies. It was observed that more PIs from Indian companies belonged to Grade A. Conclusion : we are facing the pandemic of diseases like hypertension, diabetes mellitus and other diseases. In such situation PI can play a vital role in improving the patient compliance and thereby the prognosis of disease. Hence a smart PI which is complete, reliable and up-to-date is the need of the hour.","PeriodicalId":14194,"journal":{"name":"International Journal of Pharmacological Research","volume":"40 1","pages":"349-352"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmacological Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7439/IJPR.V6I12.3657","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Package insert (PI) is the printed leaflet available with the medicines containing information about the drug based on regulatory guidelines for its safe and effective use. Information in a PI is incorporated since the developmental phase of a pharmaceutical product with careful scrutiny of available information. PI contains evidenced based information about a drug, updated from time to time as soon as relevant preclinical and clinical data were obtained. Various studies had shown poor compliance 50-60% to the medicine prescribed for the treatment of chronic conditions like hypertension, diabetes and dyslipidemia. These diseases proved to be major cause of mortality and morbidity related to cardiovascular diseases in India. The information of the PI has an important impact on patients compliance and hence effectiveness of the drug used and for health professionals they can serve as reliable and accurate sources of drug information. Material & Methods: Present study was observational and Prospective with study duration of 1 month. 93 package inserts were collected from different pharmacies of the Patna on request. Analysis of content of Package Insert was based on criteria laid down by Indian Drug and Cosmetic Rules, 1945 under section 6.2 of schedule D. Result: A total number of 106 PI were received, among which 93 PIs were analysed for the result remaining 13 PIs were discarded due to duplicity and unauthenticity. Out of them, 87 were from Indian pharmaceutical companies and 6 from multinational companies [Graph-2]. All PIs of antihypertensives and hypolipedemic were of oral preparations. Out of 93 PIs 37 were antihypertensives, 34 were antidiabetics and 22 hypolipidemics. Out of 34 anti-diabetic PIs, 22 (59.6%) were oral and 12 (40.4%) were injectable preparations. Out of 93 PIs, 40 (43%) belonged to Grade A (including all injectable preparations) and remaining 53 (57%) to Grade B. No PIs belongs to Grade C.87 PIs were from Indian companies and 6 PIs were from multinational companies. It was observed that more PIs from Indian companies belonged to Grade A. Conclusion : we are facing the pandemic of diseases like hypertension, diabetes mellitus and other diseases. In such situation PI can play a vital role in improving the patient compliance and thereby the prognosis of disease. Hence a smart PI which is complete, reliable and up-to-date is the need of the hour.
说明书中的信息:在印度东部进行的一项研究
简介:包装说明书(PI)是随药品一起提供的印刷传单,其中包含基于其安全和有效使用的监管指南的药物信息。PI中的信息自药品开发阶段起就被纳入,并对现有信息进行仔细审查。PI包含关于药物的基于证据的信息,一旦获得相关的临床前和临床数据,就会不时更新。各种研究表明,用于治疗高血压、糖尿病和血脂异常等慢性疾病的药物的依从性差达50-60%。在印度,这些疾病被证明是与心血管疾病相关的死亡和发病的主要原因。PI的信息对患者的依从性和所使用药物的有效性有重要影响,对保健专业人员来说,它们可以作为可靠和准确的药物信息来源。材料与方法:本研究为观察性前瞻性研究,研究时间为1个月。应要求从巴特那的不同药房收集了93个包装说明书。根据印度药品和化妆品法规1945年附录d第6.2节规定的标准对包装说明书的内容进行了分析。结果:共收到106份PI,其中93份PI被分析,其余13份PI因重复和不真实而被丢弃。其中87人来自印度制药公司,6人来自跨国公司[图2]。降压药和降血脂药均为口服制剂。在93名pi患者中,37名是抗高血压患者,34名是抗糖尿病患者,22名是低血脂患者。34种抗糖尿病pi中,口服22种(59.6%),注射制剂12种(40.4%)。在93个pi中,40个(43%)属于A级(包括所有注射制剂),其余53个(57%)属于b级。没有一个pi属于c级。87个pi来自印度公司,6个pi来自跨国公司。据观察,来自印度公司的pi更多属于a级。结论:我们正面临着诸如高血压、糖尿病和其他疾病的流行病。在这种情况下,PI可以在提高患者依从性从而改善疾病预后方面发挥至关重要的作用。因此,一个完整、可靠和最新的智能PI是当前的需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信